COMP <GO>
INCY vs CRL // EV/EBITDA & P/E VALUATION
Incyte Corp. (NASDAQ) VS. Charles River Laboratories International Inc. (NYSE) • 15-METRIC TALLY: INCY 10
— CRL 2
▲ EV/EBITDA & P/E VALUATION LEADER: INCY
LAST: $120.04 (-0.29%) • MKT CAP: $24.54B
valuation
12.5x
LAST: $338.54 (-5.81%) • MKT CAP: $17.16B
valuation
95.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INCY VS. CRL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INCY | CRL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 42.40% | 0.40% | +42.00 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.5x | 95.0x | -82.50 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 4.99% | 3.10% | +1.89 | INCY | /fcf-yield <GO> |
| Operating Margin | 29.50% | 0.60% | +28.90 | INCY | /operating-margins <GO> |
| Net Profit Margin | 25.00% | -3.60% | +28.60 | INCY | /net-margins <GO> |
| Revenue Growth (YoY) | 21.20% | -0.90% | +22.10 | INCY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.04 | 3.65 | +6.39 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 6/9 | +3.00 | INCY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 62.3 | -5.70 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.15 | -0.14 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.5x | 23.0x | -7.50 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.54B | $17.16B | $7.38B | INCY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INCY REV | CRL REV | INCY GROSS % | CRL GROSS % | INCY FCF | CRL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.14B | $4.02B | 92.8% | — | $1.18B | $557.0M |
| FY 2024 | $4.24B | $4.05B | 92.6% | — | $144.5M | $552.3M |
| FY 2023 | $3.70B | $4.13B | — | — | $330.2M | $498.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INCY // BETA 1.01
CRL // BETA 1.15